Dirven, I., Bertels, C., Moreels, Y., Kessels, J. I., Vanlaer, N., Vander Mijnsbrugge, A. ., Vounckx, M., Dirks, I., Raes, L., Geeraerts, X., Stevens, L., von Kemp, B., Fasolino, G., Awada, G., Janssen, T., Caljon, B., Lefevre, T., Everaert, H., Rogiers, A., ... Neyns, B. (2026). Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial. ESMO Open, 11(4), Article 106941. https://doi.org/10.1016/j.esmoop.2026.106941

@article{d15f46814c6941ea953bd738ad209369,
title = "Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial",
keywords = "BRAF/MEK inhibitors, KIT-mutation, RAF dimer inhibitor, Melanoma, Prospective clinical trial, Regorafenib",
author = "I. Dirven and C. Bertels and Y. Moreels and Kessels, {J. I.} and N. Vanlaer and {Vander Mijnsbrugge}, {A. -s.} and M. Vounckx and I. Dirks and L. Raes and X. Geeraerts and L. Stevens and {von Kemp}, B. and G. Fasolino and G. Awada and T. Janssen and B. Caljon and T. Lefevre and H. Everaert and A. Rogiers and J. Vandemeulebroucke and S. Tuyaerts and B. Neyns",
year = "2026",
month = apr,
doi = "10.1016/j.esmoop.2026.106941",
language = "English",
volume = "11",
journal = "ESMO Open",
issn = "2059-7029",
publisher = "Elsevier",
number = "4",
}